Single-cell Omics Market Analysis

Single-Cell Omics Segmentation

Application (Immunology, Neurology, Oncology, Cell Biology)

In 2035, the oncology sector is estimated to account for 46% share of the global single-cell omics market. Moreover, it garnered a revenue share of around 45% in 2022. The growth of the segment can be attributed to the rise in the number of gene therapy trials focusing on genomics in cancer care. As of 2022, over 770 of the over 1,200 active clinical studies for cell and gene therapies were in oncology. Single-cell omics enable the identification of specific gene expression patterns or genetic alterations associated with therapeutic response or resistance. By profiling individual cancer cells, researchers can identify biomarkers that predict the likelihood of response to gene therapy. Furthermore, rising investment in cancer treatment has driven the segment’s growth. By building state-of-the-art cancer treatment centers and ensuring proper testing, screening, and treatment of cancers impacted by the COVID-19 pandemic, the Australian Government is investing USD 614 million in services

End User (Pharmaceutical & Biotechnology Companies, Research Organization, Hospitals)

The research organization segment is projected to hold around 55% share of the global single-cell omics market in the year 2035. The segment will expand at a notable CAGR over the projected time period. Rising investment by private sectors to accelerate the research in the research facilities. For instance, Schmidt Futures allocated USD 550 million to the latest research facility aimed at growing single-cell proteomics technologies in March 2023. Increased investment in research facilities allows for the establishment of advanced infrastructure dedicated to single-cell omics research. This includes the procurement of advanced equipment, such as high-throughput sequencers, single-cell isolation systems, and imaging platforms.

Our in-depth analysis of the global single-cell omics market includes the following segments:

Application	Immunology Neurology Oncology Cell Biology
Product	Proteomics Metabolomics Transcriptomics
End User	Pharmaceutical & Biotechnology Companies Research Organization Hospitals

Frequently Asked Questions (FAQ)

Increasing incidences of cancer, rising investment in cell therapy, and technological advancement of single-cell techniques are the major factors driving the market growth.

The market size of single-cell omics is anticipated to attain a CAGR of around 22% over the forecast period, i.e., 2023 â€“ 2035.

The major players in the market are 10x Genomics, Inc., Becton, Dickinson and Company (BD), CELLENION, PerkinElmer Inc., ANGLE plc, Illumina, Inc., Bio-Rad Laboratories, Inc., Mission Bio Inc., Standard BioTools Inc. and Ultima Genomics, Inc.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by application, product, end user, and by region.

The oncology segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

There is no standardization and the higher cost of single-cell omics is estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

Single-cell Omics Market Analysis